ARTICLE AD BOX
The FDA has moved to exclude semaglutide, tirzepatide and liraglutide -- which are in several popular weight loss drugs -- from its 503B bulks list.
The FDA has moved to exclude semaglutide, tirzepatide and liraglutide -- which are in several popular weight loss drugs -- from its 503B bulks list.